Synovus Financial weighs merger options after drawing interest - Bloomberg
Cathie Wood’s ARK ETFs have made their daily trades public for Thursday, February 20th, 2025, revealing a continued focus on genomic innovation and a reshuffling of their technology and robotics investments. In a move that caught the attention of investors, ARK significantly increased its holdings in Beam Therapeutics Inc (NASDAQ:BEAM), purchasing a total of 170,778 shares valued at approximately $5.82 million across its ARKK and ARKG funds.
This latest acquisition of Beam Therapeutics stock underscores a growing trend, as ARK has been actively accumulating shares in the gene-editing company over the past week. On Wednesday, ARK added 23,555 shares, and earlier trades within the month of February show consistent buying, signaling a strong conviction in the company’s potential.
In contrast, ARK sold 101,874 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) through its ARKG ETF, with the sale amounting to around $852,685. This sale continues a pattern from the previous day, where ARK offloaded a more substantial portion of Adaptive Biotechnologies, totaling 708,223 shares for nearly $5.86 million.
The ARKQ ETF, focused on autonomous technology and robotics, also saw notable trades. ARK sold 15,709 shares of Rocket Lab USA Inc (NASDAQ:RKLB) for approximately $407,334, following a larger sell-off of the same stock on Wednesday, which involved 77,587 shares and a dollar value of over $2.15 million. Meanwhile, ARKQ bought 7,611 shares of Symbotic Inc (NASDAQ:SYM) for about $203,670, adding to the previous day’s purchase of 86,058 shares valued at roughly $2.39 million.
These trades reflect ARK’s strategic adjustments within its ETF portfolios, as the investment firm continues to navigate the rapidly evolving sectors of genomics, technology, and robotics. Investors and market watchers closely monitor ARK’s moves due to Cathie Wood’s reputation for identifying disruptive innovation with long-term growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.